Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-18

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison between2 Drugs in Lupus Nephritis

NCT04424602

Lupus Nephritis

COMPLETED PHASE4

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

NCT01551069

Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

COMPLETED PHASE3

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT05799378

Systemic Lupus Erythematosus

RECRUITING PHASE3

Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

NCT02444728

Thrombocytopenia

TERMINATED PHASE3

Covid-19 in Lupus Patients

NCT04355702

Systemic Lupus Erythematosus Covid-19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria. The criteria set developed by the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV .

Inclusion Criteria:

* Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
* All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

Exclusion Criteria:

* Patients diagnosed with lupus nephritis class I,II,V and VI.
* Patients received Cyclophosphamide in stead of MMF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Proliferative Nephritis Chloroquine Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lupus nephritis III or IV/chloroquine

receiving chloroquine with daily dose 5 mg/kg

Chloroquine

Intervention Type DRUG

group1 received chloroquine .

Lupus nephritis III or IV/hydroxychloroquine

receiving hydroxycholorquine with daily dose 5 mg/kg

Hydroxychloroquine

Intervention Type DRUG

Group 2 received hydroxychloroquine

Systemic lupus erythematosus

not received hydroxychloroquine nor chloroquine .

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chloroquine

group1 received chloroquine .

Intervention Type DRUG

Hydroxychloroquine

Group 2 received hydroxychloroquine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

alexoquine hydroquine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
* All patients will be received steroids , MMF and Angiotensin Converting Enzyme.